METHOD OF TREATMENT OF UNRESECTABLE PANCREATICODUODENAL CANCER Russian patent published in 2008 - IPC A61N5/10 A61K31/282 A61K31/41 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: Xeloda is introduced in dosage 850-1000 mg/m² from 1st to 16th day of treatment. Additionally platinum preparation is introduced singly on 8th day in amount 1/4-1/2 of single therapeutic dose. It is accompanied with gamma-ray therapy. Within 5 days single focal dose SFD of irradiation is 1.8-2.0 Gy. And then SFD is applied in dose 1.2-1.6 Gy twice a day until total focal dose TFD is 30-36 Gy. In 14-21 days therapy course is repeated with prescribed introduction of Xeloda within the whole course of gamma therapy until total focal dose TFD is 60-65 Gy.

EFFECT: higher degree of tumour regress, decreased radioreaction of gastrointestinal tract, improved life quality and survival time in patients suffering from severe cancers.

2 ex